FDA approves Baxalta's ADYNOVATE, a new longer- lasting recombinant factor VIII product for people with hemophilia A.
↧
FDA approves Baxalta's ADYNOVATE, a new longer- lasting recombinant factor VIII product for people with hemophilia A.